Abstract:Wei-Ying Diao, 1, &ast Cheng-Long Ding, 1, &ast Bo-Yang Yuan, 2 Zan Li, 3 Na Sun, 4 Jia-Bin Huang 5 1 Department of Pathology, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People's Republic of China; 2 Department of Acupuncture and Moxibustion, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People's Republic of China; 3 Department of Analytical Chemistry Teaching and Research, Jiamusi University, Jiamusi City, Heilongjiang Province, 154002, People's Republic of China; 4 Graduate Department, Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People's Republic of China; 5 Department of Geratology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jia-Bin Huang Email Introduction: We aim to investigate the relationship between HER2 gene phenotype and clinical characteristics, distribution and prognosis of non-small cell lung cancer (NSCLC) patients. Methods: A total of 249 NSCLC patients admitted to the oncology department of our hospital from January 2015 to January 2018 were retrospectively analyzed. The clinicopathological information, CT signs, clinical efficacy and long-term prognosis were collected and compared. Results: A total of 249 NSCLC patients underwent HER2 gene testing, 21 of them (8.43%) complied with HER2 alterations [HER2 (+)], and there were significant differences in tumor stages among patients with different HER2 phenotypes ( P 0.05). The disease control rate of HER2 (+) patients was significantly lower than that of HER2 (-) patients, and the 12-month progression-free survival rate and survival rate of HER2 (+) patients were significantly higher than those of HER2 (-) patients ( P < 0.05). There was no significant difference in the incidence of ADR among HER2 patients with different phenotypes, but the incidence of ADR (adverse drug reaction) in HER2 (+) patients with Grade 3 or 4 was significantly higher than that in the control group ( P < 0.05). Discussion: The incidence of HER2 gene mutations in NSCLC patients is relatively low, but it is far commoner in patients with stage IIIB∼IV, among which exon 20 mutations are the most prevalent. In CT signs, the lesion lobulated sign/spiculated sign, necrosis signs, and pleural depression signs are related to HER2 gene mutations. In addition, HER2 gene mutations play a crucial role in the clinical prognosis and treatment safety of patients. Keywords: non-small cell lung cancer, HER2 genotype, CT signs, afatinib As one of the most prevalent malignant tumors worldwide, lung cancer has become the top cause of cancer-related death in the urban population of China. Non-small cell lung cancer (NSCLC) includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, in which cancer cells grow and divide more slowly, and spread and metastasize are less drastic. 1,2 NSCLC accounts for about 80% of overall lung cancers, and approximately 75% of patients have progressed in the advanced stage when diagnosed, with somber 5-year survival rate. 3 At present, the treatment of NSCLC mainly includes surgery, radiotherapy, chemotherapy, immunotherapy, etc. A large number of studies have shown that the occurrence and development of lung cancer are consequent to the unbalanced regulation of multiple gene expression, which is closely related to the stability of genes in organisms. 4,5 Human Epithelial Factor Receptor-2 (HER2) is a member of the epithelial factor receptor family. Studies demonstrated that HER2 overexpression is an enhancer of EGFR signaling, and it plays a role in signal transduction in cancer development and progress when HER2 is dysfunctional. 6 Afatinib and trezizumab have been recommended as targeted therapies for patients with HER2 mutation -Abstract Truncated-

HER3 is widely expressed across diverse subtypes of NSCLC in a retrospective analysis of archived tissue samples

HER2 Protein Expression Level is Positively Associated with the Efficacy of Neoadjuvant Systemic Therapy in HER2-positive Breast Cancer

Egfr, Her2 and Her3 Expression in Esophageal Primary Tumours and Corresponding Metastases

The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study

EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases

Egfr and Her2 Expression in Primary Cervical Cancers and Corresponding Lymph Node Metastases: Implications for Targeted Radiotherapy

HER-2 Mutations in Chinese Lung Adenocarcinoma Patients with Negative EGFR Mutations.

T Cell Immunoglobulin and Mucin-Domain Containing-3 in Non-Small Cell Lung Cancer

Abstract 5320: Targeting HER3 and EGFR in NRG1 Positive and HER3 Mutated Lung Squamous Cell Carcinoma

Comparison of the Epidermal Growth Factor Receptor Protein Expression Between Primary Non-Small Cell Lung Cancer and Paired Lymph Node Metastases: Implications for Targeted Nuclide Radiotherapy.

Targeting HER3 to overcome EGFR TKI resistance in NSCLC

A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance

Expression and clinical significance of HER3 in breast carcinoma tissue

Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer

Her2 Expression in Primary Gastric Cancers and Paired Synchronous Lymph Node and Liver Metastases. A Possible Road to Target Her2 with Radionuclides

HER3 overexpression: a predictive marker for poor prognosis in advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors

Expression and Association of HER2 with Prognosis in Early-Stage (T1–T2N0M0) Non-Small Cell Lung Cancer

Abstract LB-237: Targeting HER3 and IGF1R in NRG1 High Lung Squamous Cell Carcinoma

Abstract 6190: Patterns of EGFR and HER3 co-expression in solid tumors

Prognostic Significance of HER3 in Patients with Malignant Solid Tumors.

HER3: Updates and current biology function, targeted therapy and pathologic detecting methods